Compare FLNC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNC | NVAX |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.3B |
| IPO Year | 2021 | 1996 |
| Metric | FLNC | NVAX |
|---|---|---|
| Price | $9.96 | $9.59 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 17 | 9 |
| Target Price | ★ $15.71 | $11.33 |
| AVG Volume (30 Days) | ★ 5.3M | 4.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,830,000.00 | $1,123,479,000.00 |
| Revenue This Year | $51.23 | N/A |
| Revenue Next Year | $21.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $6.79 | $6.20 |
| 52 Week High | $33.51 | $11.85 |
| Indicator | FLNC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 33.04 | 53.12 |
| Support Level | N/A | $9.14 |
| Resistance Level | $15.89 | $10.26 |
| Average True Range (ATR) | 0.51 | 0.63 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 3.62 | 42.78 |
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.